BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Clark KEN, Collas O, Lachmann H, Singh A, Buckley J, Bhagani S. Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series. Rheumatol Adv Pract 2020;4:rkaa040. [PMID: 32964179 DOI: 10.1093/rap/rkaa040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Hendricks CL, Herd C, Nel M, Tintinger G, Pepper MS. The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time. Front Med (Lausanne) 2021;8:604087. [PMID: 33681243 DOI: 10.3389/fmed.2021.604087] [Reference Citation Analysis]
2 Wiese MD, Berry MJ, Hissaria P, Darby JRT, Morrison JL. COVID-19: can we treat the mother without harming her baby? J Dev Orig Health Dis 2021;:1-11. [PMID: 33487213 DOI: 10.1017/S2040174420001403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Barkas F, Ntekouan SF, Kosmidou M, Liberopoulos E, Liontos A, Milionis H. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis. Rheumatology (Oxford) 2021:keab447. [PMID: 33999135 DOI: 10.1093/rheumatology/keab447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Retamozo S, Brito-Zerón P, Sisó-Almirall A, Flores-Chávez A, Soto-Cárdenas MJ, Ramos-Casals M. Haemophagocytic syndrome and COVID-19. Clin Rheumatol 2021;40:1233-44. [PMID: 33389315 DOI: 10.1007/s10067-020-05569-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
5 Brain D, Plant-Hately A, Heaton B, Arshad U, David C, Hedrich C, Owen A, Liptrott NJ. Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19. Adv Drug Deliv Rev 2021;178:113848. [PMID: 34182016 DOI: 10.1016/j.addr.2021.113848] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
6 Geng J, Wang F, Huang Z, Chen X, Wang Y. Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19. Cytokine 2021;143:155544. [PMID: 33926774 DOI: 10.1016/j.cyto.2021.155544] [Reference Citation Analysis]
7 Al-Hajeri H, Baroun F, Abutiban F, Al-Mutairi M, Ali Y, Alawadhi A, Albasri A, Aldei A, AlEnizi A, Alhadhood N, Al-Herz A, Alkadi A, Alkanderi W, Almathkoori A, Almutairi N, Alsayegh S, Alturki A, Bahbahani H, Dehrab A, Ghanem A, Haji Hasan E, Hayat S, Saleh K, Tarakmeh H. Therapeutic role of immunomodulators during the COVID-19 pandemic - a narrative review. Postgrad Med 2022. [PMID: 35086413 DOI: 10.1080/00325481.2022.2033563] [Reference Citation Analysis]